Page last updated: 2024-09-04

edotreotide and arginine

edotreotide has been researched along with arginine in 2 studies

Compound Research Comparison

Studies (edotreotide)	Trials (edotreotide)	Recent Studies (post-2010) (edotreotide)	Studies (arginine)	Trials (arginine)	Recent Studies (post-2010) (arginine)
206	34	86	46,388	1,688	11,176

Protein Interaction Comparison

Protein	Taxonomy	edotreotide (IC50)	arginine (IC50)
Cationic amino acid transporter 3	Homo sapiens (human)		283

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barone, R; Bouterfa, H; Carlier, P; Chen, T; de Camps, J; Jamar, F; Krenning, EP; Kvols, LK; Labar, D; Mathieu, I; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Walrand, S	1
Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Kahn, D; Karwal, M; Madsen, M; Menda, Y; Miller, S; O'Dorisio, S; O'Dorisio, T; Ponto, J; Squires, S; Walkner, W	1

Trials

2 trial(s) available for edotreotide and arginine

Article	Year
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:4 Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes	2003
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment. Cancer biotherapy & radiopharmaceuticals, 2004, Volume: 19, Issue:1 Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes	2004

Article

Year

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.

European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:4

Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes

2003

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.

Cancer biotherapy & radiopharmaceuticals, 2004, Volume: 19, Issue:1

Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes

2004